Comparative Pharmacology
Head-to-head clinical analysis: LIBRITABS versus TRIAZOLAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIBRITABS versus TRIAZOLAM.
LIBRITABS vs TRIAZOLAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Libritabs (chlordiazepoxide) is a benzodiazepine that binds to GABA-A receptors at the gamma subunit, potentiating GABAergic inhibition and producing anxiolytic, sedative, and anticonvulsant effects.
Triazolam is a benzodiazepine that binds to GABA-A receptors at the alpha-1 subunit, potentiating the inhibitory effects of GABA and increasing chloride ion influx, leading to neuronal hyperpolarization and sedation.
5-10 mg orally 3-4 times daily; up to 30 mg/day in divided doses for severe anxiety.
0.125-0.25 mg orally once daily at bedtime; maximum 0.5 mg/day.
None Documented
None Documented
Terminal elimination half-life is 15-20 hours; clinical context: steady-state reached in 3-5 days with daily dosing, prolonged in hepatic impairment.
Clinical Note
moderateTriazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Triazolam is combined with Fluticasone propionate."
Clinical Note
moderateTriazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Triazolam."
Clinical Note
moderateTriazolam + Erythromycin
"The serum concentration of Erythromycin can be increased when it is combined with Triazolam."
Clinical Note
moderateTriazolam + Cyclosporine
1.5-5.5 hours (mean 2-4 hours) in healthy adults; prolonged in hepatic cirrhosis and elderly.
Renal: 70-80% as unchanged drug and glucuronide conjugate; fecal: 15-20% via biliary elimination.
Primarily renal: approximately 80% as metabolites, less than 2% unchanged; biliary/fecal: minor (about 8-10%).
Category C
Category D/X
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Triazolam."